Abstract

Objective: Using a single-center cohort of Chinese adult patients with systemic lupus erythematosus (SLE), we analyzed predictors of clinical response during the year after bone marrow-derived (BM) and/or umbilical cord-derived (UC) allogeneic mesenchymal stem cell (MSC) treatment.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call